Completed
A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector
NCT02124798
- Conditions
- Autoimmune Diseases, Connective Tissue Diseases, Immune System Diseases, +3 more
- Locations
-
- GSK Investigational Site Birmingham, Alabama, United States
- GSK Investigational Site Tuscaloosa, Alabama, United States
- GSK Investigational Site Gilbert, Arizona, United States
- GSK Investigational Site Mesa, Arizona, United States